KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $317000.0.

  • Vir Biotechnology's Capital Expenditures fell 8854.77% to $317000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 529.16%. This contributed to the annual value of $7.3 million for FY2024, which is 6615.68% down from last year.
  • Vir Biotechnology's Capital Expenditures amounted to $317000.0 in Q3 2025, which was down 8854.77% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Vir Biotechnology's Capital Expenditures registered a high of $20.6 million during Q2 2022, and its lowest value of $317000.0 during Q3 2025.
  • In the last 5 years, Vir Biotechnology's Capital Expenditures had a median value of $2.8 million in 2024 and averaged $6.5 million.
  • Per our database at Business Quant, Vir Biotechnology's Capital Expenditures surged by 227496.25% in 2022 and then tumbled by 9295.76% in 2024.
  • Vir Biotechnology's Capital Expenditures (Quarter) stood at $13.1 million in 2021, then fell by 3.77% to $12.6 million in 2022, then tumbled by 87.79% to $1.5 million in 2023, then rose by 29.97% to $2.0 million in 2024, then crashed by 84.11% to $317000.0 in 2025.
  • Its Capital Expenditures stands at $317000.0 for Q3 2025, versus $2.5 million for Q2 2025 and $1.6 million for Q1 2025.